Pulmonology

At ATS 2023, Dr. Galiatsatos illuminates what makes lung cancer screening different and how the screening approach is changing.

In an interview at ATS 2023, Dr. Rutland stresses the importance of studying the immune system's response to various diseases, emphasizing the potential impact of pipeline molecules.

A post hoc analysis shows benralizumab was even more efficacious in patients with concomitant nasal polyps at both 6 and 12 months.

Dr. Panagis Galiatsatos explains the new lung cancer screening aims to address the disparities of disease onset and progression across different racial populations.

Though still not in abundance on the market, ICS/LAMA/LABA triple-therapy single inhaler treatment options are becoming more valued for COPD exacerbation and comorbid disease risk.

An analysis of the phase 3 NAVIGATOR trial shows tezepelumab did not provide differing efficacy among men and women, despite historic trends of disparate severe asthma outcomes among sexes.

Unlike other screenings, lung cancer screening is new and patients need to know what happens next, according to Dr. Panagis Galiatsatos.

Dupilumab demonstrates significant improvements in patients with COPD, type 2 inflammation by reducing exacerbations, improving lung function and quality of life, and alleviating respiratory symptoms.

An analysis of the COPDGene Study presented at ATS 2023 suggests presence of mucus plugs in medium- to large-sized airways were associated with an increased risk of mortality in adjusted models.

As a result of these practices, asthma disparities have been amplified due to the concentration of poverty, heightened exposure to environmental hazards, and inadequate housing quality in these communities.

The increased use of tobacco-free nicotine products highlights the need for physicians to stay informed about nicotine pouches and be prepared for discussions with their patients.

Relocation led to a reduction in asthma exacerbations, exceeding the effect of inhaled corticosteroids, and was similar to biologic agents.

The phase 3 clinical trials evaluating ziritaxestat for treating idiopathic pulmonary fibrosis showed no improvement in clinical outcomes leading to the termination of the trials due to lack of efficacy.

Allergic disease and asthma have become distinctly linked among a significant proportion of patients. A pulmonologist and allergist review diagnostics, guidelines and research relevant to the interplay.

At West Penn Hospital, the harmonica program, currently in the pilot phase, aims to demonstrate its benefits in improving respiratory symptoms, reducing exacerbations, and enhancing patients' quality of life.

"Playing the harmonica has a therapeutic effect because of the pursed lip breathing technique it requires," Dr. Becky Jordan says in an interview.

Results from the NIH RECOVER Initiative study show an 89% risk of long COVID in women with sleep apnea and 59% in men when compared with adults without the condition.

Results showed standardized reporting was frequently used in low-dose computed tomography lung screening, with the majority of instances being considered reportable to the clinician and requiring follow-up.

Data show older age, being female, having a high BMI, smoking, comorbidities, and previous hospitalization or ICU admission with COVID-19 were associated with an increased risk of developing Post-COVID-19 condition.

Data indicate higher BMI is associated with an increased risk of severe respiratory disease, including COVID-19, with the highest risk observed in those with a BMI in the range of 35-60.

The US Preventive Services Task Force recommends screening adults at increased risk for latent tuberculosis infection, as evidence demonstrates the accuracy of available tests and preventive treatment regimens provide a moderate net benefit.

Data reveal 42 SNPs associated with eosinophil counts, 18 SNPs with airway obstruction, and 21 SNPs with atopy.

The research letter explains Native American ancestry was associated with a lower risk of asthma while African-American populations had an increased risk of asthma.

Dupilumab shows significant reduction in annualized asthma exacerbation rate and improvement in lung function and asthma control in children with type 2 asthma, especially those with evidence of allergic asthma.

There was an increase in depression in the cystic fibrosis group, as well as an increase in anxiety in cystic fibrosis caregivers during the pandemic.